Geovax Labs Inc
1.95 - 2.3
0.5495 - 7.5
Join Discuss about GOVX with like-minded investors
BKSY - 2.60 / 2.75 / 3.00 lines to short with a 3.15 STOP ELEV - Ideally 4.10 / 4.20 / 4.30 lines to scale in short with a stop over previous days HOD GOVX - Felt like it was trapping shorts yesterday, then had a midday offering and trapped longs, now this morning it feels like it trapped shorts again. This is VERY ODD PRICE ACTION. What makes it odd? the fact that it is super unpredictable. When a stock is unpredictable like this... how can we trade it?! Might be best to avoid it and wait. Who knows, maybe it has enough shorts now to ramp it back over $3, or this is just a pre market pump before a dump. Either way it is pretty unpredictable now, so I will wait for the open and to see what the volume and price action tells us before I continue with a plan MICS - Low hanging fruit. Maybe a pop toward 3.60 / 4.00 / 4.20 to short for a nail and bail ONLY https://myinvestingclub.com/trading/how-to-scale-into-the-watch-list-when-to-use-max-full-size-when-trading-30-rule-watch-list/
38 Replies 10 👍 11 🔥
oooh I went to a meeting and I see GOVX destroyed when I come back... was that an offering?
42 Replies 15 👍 15 🔥
besides GOVX SIGA SNAP and RDBX what other 2 did you trade?
76 Replies 13 👍 11 🔥
Next Dividend Date
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.
CEO: David Dodd
HQ: 11465 Johns Creek Pkwy Ste 400 Smyrna, 30080 Georgia